SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-251073
Filing Date
2023-10-05
Accepted
2023-10-05 07:15:00
Documents
14
Period of Report
2023-10-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d555980d8k.htm   iXBRL 8-K 25483
2 EX-99.1 d555980dex991.htm EX-99.1 37629
6 GRAPHIC g555980img01.jpg GRAPHIC 5711
  Complete submission text file 0001193125-23-251073.txt   197778

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA apls-20231005.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20231005_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20231005_pre.xml EX-101.PRE 10812
8 EXTRACTED XBRL INSTANCE DOCUMENT d555980d8k_htm.xml XML 3202
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 231309804
SIC: 2834 Pharmaceutical Preparations